Rego-Lorca Daniela, Valverde-Megías Alicia, Fernández-Vigo José Ignacio, Oribio-Quinto Carlos, Murciano-Cespedosa Antonio, Sánchez-Quirós Julia, Donate-López Juan, García-Feijóo Julián
Department of Ophthalmology, San Carlos Clinical Hospital, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.
Centro Internacional de Oftalmología Avanzada, 28010 Madrid, Spain.
J Clin Med. 2022 Aug 28;11(17):5063. doi: 10.3390/jcm11175063.
Consequences of the COVID-19 pandemic on medical care have been extensively analyzed. Specifically, in ophthalmology practice, patients suffering age-related macular degeneration (AMD) represent one of the most affected subgroups. After reporting the acute consequences of treatment suspension in neovascular AMD, we have now evaluated these same 242 patients (270 eyes) to assess if prior functional and anatomical situations can be restored after twelve months of regular follow-up and treatment. We compared data from visits before COVID-19 outbreak and the first visit after lockdown with data obtained in subsequent visits, until one year of follow-up was achieved. For each patient, rate of visual loss per year before COVID-19 pandemic, considered “natural history of treated AMD”, was calculated. This rate of visual loss significantly increased during the lockdown period and now, after twelve months of regular follow-up, is still higher than before COVID outbreak (3.1 vs. 1.6 ETDRS letters/year, p < 0.01). Percentage of OCT images showing active disease is now lower than before the lockdown period (51% vs. 65.3%, p = 0.0017). Although anatomic deterioration, regarding signs of active disease, can be apparently fully restored, our results suggest that functional consequences of temporary anti-VEGF treatment suspension are not entirely reversible after 12 months of treatment, as BCVA remains lower and visual loss rate is still higher than before the COVID-19 pandemic.
新冠疫情对医疗保健的影响已得到广泛分析。具体而言,在眼科实践中,患有年龄相关性黄斑变性(AMD)的患者是受影响最严重的亚组之一。在报告了新生血管性AMD治疗暂停的急性后果后,我们现在对这242名患者(270只眼)进行了评估,以确定在经过十二个月的定期随访和治疗后,之前的功能和解剖状况是否能够恢复。我们将新冠疫情爆发前的就诊数据和封锁后的首次就诊数据与后续就诊直至随访一年所获得的数据进行了比较。对于每位患者,计算了新冠疫情大流行前每年的视力丧失率,即“治疗后AMD的自然病程”。在封锁期间,这种视力丧失率显著增加,而现在,经过十二个月的定期随访后,仍高于新冠疫情爆发前(3.1对1.6 ETDRS字母/年,p<0.01)。显示活动性疾病的OCT图像百分比现在低于封锁期之前(51%对65.3%,p = 0.0017)。尽管就活动性疾病迹象而言,解剖学恶化似乎可以完全恢复,但我们的结果表明,在治疗十二个月后,临时抗VEGF治疗暂停的功能后果并未完全可逆,因为最佳矫正视力(BCVA)仍然较低,视力丧失率仍高于新冠疫情大流行之前。